Freenome

Freenome is a healthcare company focused on developing next-generation blood tests for early cancer detection by leveraging a multiomics platform which integrates machine learning with molecular biology. The aim is to identify early signs of cancer from circulating biomarkers derived from both tumor and non-tumor sources, making cancer screening more accessible and tailored to different types of cancer​.

Key Features:

• Multiomics Platform: Freenome utilizes a comprehensive multiomics platform that combines molecular biology and machine learning to discern cancer-associated patterns among billions of circulating biomarkers. This platform is at the heart of their blood tests development, providing the technological backbone for detecting early signs of various cancers.
• Early Cancer Detection Blood Tests: With an emphasis on early detection, Freenome is developing blood tests that are easy to administer as part of routine healthcare. Their first blood test in development targets colorectal cancer, the second deadliest cancer in the US, aiming to change the statistics surrounding its detection and treatment. They are also working on multi-cancer screening tests, ensuring each test is optimized for different cancer signals, screening goals, and diagnostic and care pathways to ultimately improve patient outcomes.
• Clinical Studies for Validation: Freenome drives the discovery and validation of its early cancer detection tests through rigorous clinical studies, in partnership with leading academic and health organizations. They have conducted the largest clinical study validating a blood-based colorectal screening test named PREEMPT CRC, and are extending their studies to multi-cancer early detection with two large studies named The Vallania Study and The Sanderson Study, aimed at refining and developing tests to detect multiple cancers.

Main Use Cases:

• Colorectal Cancer Screening: The development of an accessible blood test for colorectal cancer screening aims to improve the statistics surrounding colorectal cancer detection and treatment, making it easier for individuals to get screened, thereby detecting colorectal cancer in its earliest stages.
• Multi-Cancer Screening: By extending their multiomics platform beyond colorectal cancer, Freenome is in the process of developing and validating blood tests for the detection of multiple cancers, which would be a significant step towards comprehensive early cancer detection, catering to the diverse nature of cancers.
• Clinical Research and Real-World Impact: Through their clinical studies, Freenome is bridging the gap between clinical research and real-world clinical impact. Their studies are aimed at refining and further developing tests to detect multiple cancers, ensuring that the tests are validated and reliable for real-world usage. This provides a solid foundation for the practical application of their early cancer detection technology in healthcare settings.

Key Features:

• Multiomics Platform: Freenome utilizes a comprehensive multiomics platform that combines molecular biology and machine learning to discern cancer-associated patterns among billions of circulating biomarkers. This platform is at the heart of their blood tests development, providing the technological backbone for detecting early signs of various cancers.
• Early Cancer Detection Blood Tests: With an emphasis on early detection, Freenome is developing blood tests that are easy to administer as part of routine healthcare. Their first blood test in development targets colorectal cancer, the second deadliest cancer in the US, aiming to change the statistics surrounding its detection and treatment. They are also working on multi-cancer screening tests, ensuring each test is optimized for different cancer signals, screening goals, and diagnostic and care pathways to ultimately improve patient outcomes.
• Clinical Studies for Validation: Freenome drives the discovery and validation of its early cancer detection tests through rigorous clinical studies, in partnership with leading academic and health organizations. They have conducted the largest clinical study validating a blood-based colorectal screening test named PREEMPT CRC, and are extending their studies to multi-cancer early detection with two large studies named The Vallania Study and The Sanderson Study, aimed at refining and developing tests to detect multiple cancers.

Main Use Cases:

• Colorectal Cancer Screening: The development of an accessible blood test for colorectal cancer screening aims to improve the statistics surrounding colorectal cancer detection and treatment, making it easier for individuals to get screened, thereby detecting colorectal cancer in its earliest stages.
• Multi-Cancer Screening: By extending their multiomics platform beyond colorectal cancer, Freenome is in the process of developing and validating blood tests for the detection of multiple cancers, which would be a significant step towards comprehensive early cancer detection, catering to the diverse nature of cancers.
• Clinical Research and Real-World Impact: Through their clinical studies, Freenome is bridging the gap between clinical research and real-world clinical impact. Their studies are aimed at refining and further developing tests to detect multiple cancers, ensuring that the tests are validated and reliable for real-world usage. This provides a solid foundation for the practical application of their early cancer detection technology in healthcare settings.